XBP1 and Miyoshi myopathy: Moreover, toyocamycin suppressed the constitutive activation of XBP1 expression in MM cell lines, inhibited tumor growth in a MM xenograft in vivo model, and synergistically enhanced the chemotherapeutic effect of bortezomib in MM cells, including the bortezomib-resistant ones [127].